TRIM56 and metabolic dysfunction-associated steatotic liver disease: On the basis of the observations that TRIM56 protein expression was decreased in NAFLD mice, humans, and PO-challenged hepatocytes, we hypothesized that TRIM56 could potentially confer protection against NAFLD.